Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
Adolescent
Adult
Aged
Cohort Studies
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
/ mortality
Humans
Male
Middle Aged
Models, Statistical
Myelodysplastic Syndromes
/ mortality
Nomograms
Prognosis
Risk Assessment
/ standards
Risk Factors
Survival Rate
Transplantation, Homologous
Young Adult
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
02
07
2018
accepted:
09
01
2019
pubmed:
19
1
2019
medline:
21
5
2020
entrez:
19
1
2019
Statut:
ppublish
Résumé
The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1%, and platelet count ≤50 × 10
Identifiants
pubmed: 30655377
pii: haematol.2018.200808
doi: 10.3324/haematol.2018.200808
pmc: PMC6518902
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-936Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Biol Blood Marrow Transplant. 2018 Oct;24(10):2101-2109
pubmed: 29777868
Lancet. 2014 Jun 28;383(9936):2239-52
pubmed: 24656536
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
J Clin Oncol. 2017 Jul 1;35(19):2157-2164
pubmed: 28463633
Ann Intern Med. 1993 Feb 1;118(3):173-8
pubmed: 8380242
JAMA. 2011 Nov 2;306(17):1874-83
pubmed: 22045765
Semin Hematol. 2017 Jul;54(3):154-158
pubmed: 28958289
Bone Marrow Transplant. 2016 Jun;51(6):786-92
pubmed: 26901709
J Clin Oncol. 2016 Jun 1;34(16):1864-71
pubmed: 27044940
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Blood. 2016 May 19;127(20):2427-38
pubmed: 26884374
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Haematologica. 2015 Mar;100(3):400-8
pubmed: 25552702
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Blood. 2017 Apr 27;129(17):2347-2358
pubmed: 28223278
Blood. 2014 Apr 10;123(15):2333-42
pubmed: 24558201
Clin Infect Dis. 2014 Aug 15;59(4):473-81
pubmed: 24850801
Biol Blood Marrow Transplant. 2017 Dec;23(12):2184-2191
pubmed: 28864138
J Clin Oncol. 2016 Oct 20;34(30):3627-3637
pubmed: 27601546
J Clin Oncol. 2012 Mar 10;30(8):820-9
pubmed: 22331955
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Blood. 2012 Jun 14;119(24):5632-9
pubmed: 22504927
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
N Engl J Med. 2017 Dec 21;377(25):2433-2444
pubmed: 29211658